Immediate Impact

1 from Science/Nature 64 standout
Sub-graph 1 of 24

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Nanoarchitectonics of in Situ Antibiotic-Releasing Acicular Nanozymes for Targeting and Inducing Cuproptosis-like Death to Eliminate Drug-Resistant Bacteria
2024 Standout
2 intermediate papers

Works of Jüri Teras being referenced

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
2008
Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam
2005

Author Peers

Author Last Decade Papers Cites
Jüri Teras 56 125 48 145 103 18 393
J. B. Gunnison 42 95 20 79 120 20 443
H. Drugeon 33 90 29 137 191 35 452
Yoko Takayama 24 107 31 120 45 42 337
Alper Tünger 57 113 12 102 61 37 407
B J McGrath 39 114 12 136 157 10 340
P. J. Wilkinson 15 99 30 90 135 15 340
Patricia Farrel 50 172 7 117 66 15 434
R. Kohlmann 27 93 11 127 50 21 417
R R Packer 50 118 8 185 202 22 409
E. Diza 35 94 15 120 39 23 438

All Works

Loading papers...

Rankless by CCL
2026